Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial.

Restelli, Umberto; Fabbiani, Massimiliano; Di Giambenedetto, Simona; Nappi, Carmela; Croce, Davide

Restelli, Umberto; Fabbiani, Massimiliano; Di Giambenedetto, Simona; Nappi, Carmela; Croce, Davide.

Afiliação

Restelli U; Center for Health Economics, Social and Health Care Management, LIUC - Università Cattaneo, Castellanza, Italy.
Fabbiani M; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Di Giambenedetto S; Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart.
Nappi C; Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart.
Croce D; Health Economics, Bristol Myers Squibb S.r.l., Rome, Italy.

Clinicoecon Outcomes Res ; 9: 569-571, 2017.

Article em En | MEDLINE | ID: mdl-29026324

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Temas: ECOS / Financiamentos_gastos Bases de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Clinicoecon Outcomes Res Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Itália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google